The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective obser...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2024-07, Vol.115 (7), p.2384-2395 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2395 |
|---|---|
| container_issue | 7 |
| container_start_page | 2384 |
| container_title | Cancer science |
| container_volume | 115 |
| creator | Shimazu, Yutaka Kanda, Junya Suzuki, Kazuhito Wada, Akinori Kikuchi, Taku Ikeda, Takashi Tsukada, Nobuhiro Miwa, Akiyoshi Itagaki, Mitsuhiro Kako, Shinichi Nishiwaki, Kaichi Ota, Shuichi Fujiwara, Shin‐ichiro Kataoka, Keisuke Doki, Noriko Sawa, Masashi Hiramoto, Nobuhiro Nishikawa, Akinori Imai, Toshi Ichinohe, Tatsuo Kanda, Yoshinobu Atsuta, Yoshiko Kawamura, Koji |
| description | The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age |
| doi_str_mv | 10.1111/cas.16198 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11247619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3079030812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4048-7e4f221c5256c5f57153cd9df918efd8db2c1c4616feadd168a7638f1118cc123</originalsourceid><addsrcrecordid>eNp1kUtrVTEUhYMotlYH_gEJONHBaZNzcpKckZSLLyg4sI5Dbh63KXkc86jcf2-8txYVzGQH9sdirb0AeInROe7vQslyjile-CNwiieyDAwh-vjwZ8OCpvEEPCvlFqGJkoU8BScTZzMjGJ0Cd31joAurVBUmC7XMsrbQgtzCNZuajazBxL6LMDRf3eoNDHvjU5BwldX1XYEtapN3ycUdlK0mn3apFVizjGX1MtbOpfgcPLHSF_Pifp6Bbx_eX28-DVdfPn7eXF4NiiDCB2aIHUes5nGmarYzw_Ok9KLtgrmxmuvtqLAiFFNrpNaYcsnoxG2_A1cKj9MZeHfUXds2GK26wyy9WLMLMu9Fkk78vYnuRuzSncB4JKxfsSu8uVfI6XszpYrgijK-RzE9mJjQTCkliJKOvv4HvU0tx56vU6yfHvGDpbdHSuVUSjb2wQ1G4leDojcoDg129tWf9h_I35V14OII_HDe7P-vJDaXX4-SPwFLl6hl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3079030812</pqid></control><display><type>article</type><title>The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Shimazu, Yutaka ; Kanda, Junya ; Suzuki, Kazuhito ; Wada, Akinori ; Kikuchi, Taku ; Ikeda, Takashi ; Tsukada, Nobuhiro ; Miwa, Akiyoshi ; Itagaki, Mitsuhiro ; Kako, Shinichi ; Nishiwaki, Kaichi ; Ota, Shuichi ; Fujiwara, Shin‐ichiro ; Kataoka, Keisuke ; Doki, Noriko ; Sawa, Masashi ; Hiramoto, Nobuhiro ; Nishikawa, Akinori ; Imai, Toshi ; Ichinohe, Tatsuo ; Kanda, Yoshinobu ; Atsuta, Yoshiko ; Kawamura, Koji</creator><creatorcontrib>Shimazu, Yutaka ; Kanda, Junya ; Suzuki, Kazuhito ; Wada, Akinori ; Kikuchi, Taku ; Ikeda, Takashi ; Tsukada, Nobuhiro ; Miwa, Akiyoshi ; Itagaki, Mitsuhiro ; Kako, Shinichi ; Nishiwaki, Kaichi ; Ota, Shuichi ; Fujiwara, Shin‐ichiro ; Kataoka, Keisuke ; Doki, Noriko ; Sawa, Masashi ; Hiramoto, Nobuhiro ; Nishikawa, Akinori ; Imai, Toshi ; Ichinohe, Tatsuo ; Kanda, Yoshinobu ; Atsuta, Yoshiko ; Kawamura, Koji</creatorcontrib><description>The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara– group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.
To clarify the prognostic impact of daratumumab (Dara) before autologous stem cell transplantation (ASCT) on multiple myeloma (MM), we performed a retrospective observational analysis. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.</description><identifier>ISSN: 1347-9032</identifier><identifier>ISSN: 1349-7006</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.16198</identifier><identifier>PMID: 38757410</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Age ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - therapeutic use ; Autografts ; autologous stem cell transplantation ; CD38 antigen ; Chi-square test ; Confidence intervals ; daratumumab ; Female ; Gender ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Male ; Medical prognosis ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Multiple Myeloma - therapy ; Multivariate analysis ; Original ; ORIGINAL ARTICLE ; Prognosis ; Progression-Free Survival ; response ; Retrospective Studies ; Software packages ; Stem cell transplantation ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Cancer science, 2024-07, Vol.115 (7), p.2384-2395</ispartof><rights>2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4048-7e4f221c5256c5f57153cd9df918efd8db2c1c4616feadd168a7638f1118cc123</cites><orcidid>0000-0002-6704-3633 ; 0000-0002-8263-9902 ; 0000-0002-1604-7220</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247619/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247619/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38757410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimazu, Yutaka</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Suzuki, Kazuhito</creatorcontrib><creatorcontrib>Wada, Akinori</creatorcontrib><creatorcontrib>Kikuchi, Taku</creatorcontrib><creatorcontrib>Ikeda, Takashi</creatorcontrib><creatorcontrib>Tsukada, Nobuhiro</creatorcontrib><creatorcontrib>Miwa, Akiyoshi</creatorcontrib><creatorcontrib>Itagaki, Mitsuhiro</creatorcontrib><creatorcontrib>Kako, Shinichi</creatorcontrib><creatorcontrib>Nishiwaki, Kaichi</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><creatorcontrib>Fujiwara, Shin‐ichiro</creatorcontrib><creatorcontrib>Kataoka, Keisuke</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Sawa, Masashi</creatorcontrib><creatorcontrib>Hiramoto, Nobuhiro</creatorcontrib><creatorcontrib>Nishikawa, Akinori</creatorcontrib><creatorcontrib>Imai, Toshi</creatorcontrib><creatorcontrib>Ichinohe, Tatsuo</creatorcontrib><creatorcontrib>Kanda, Yoshinobu</creatorcontrib><creatorcontrib>Atsuta, Yoshiko</creatorcontrib><creatorcontrib>Kawamura, Koji</creatorcontrib><title>The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara– group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.
To clarify the prognostic impact of daratumumab (Dara) before autologous stem cell transplantation (ASCT) on multiple myeloma (MM), we performed a retrospective observational analysis. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Autografts</subject><subject>autologous stem cell transplantation</subject><subject>CD38 antigen</subject><subject>Chi-square test</subject><subject>Confidence intervals</subject><subject>daratumumab</subject><subject>Female</subject><subject>Gender</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - therapy</subject><subject>Multivariate analysis</subject><subject>Original</subject><subject>ORIGINAL ARTICLE</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>response</subject><subject>Retrospective Studies</subject><subject>Software packages</subject><subject>Stem cell transplantation</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>1347-9032</issn><issn>1349-7006</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtrVTEUhYMotlYH_gEJONHBaZNzcpKckZSLLyg4sI5Dbh63KXkc86jcf2-8txYVzGQH9sdirb0AeInROe7vQslyjile-CNwiieyDAwh-vjwZ8OCpvEEPCvlFqGJkoU8BScTZzMjGJ0Cd31joAurVBUmC7XMsrbQgtzCNZuajazBxL6LMDRf3eoNDHvjU5BwldX1XYEtapN3ycUdlK0mn3apFVizjGX1MtbOpfgcPLHSF_Pifp6Bbx_eX28-DVdfPn7eXF4NiiDCB2aIHUes5nGmarYzw_Ok9KLtgrmxmuvtqLAiFFNrpNaYcsnoxG2_A1cKj9MZeHfUXds2GK26wyy9WLMLMu9Fkk78vYnuRuzSncB4JKxfsSu8uVfI6XszpYrgijK-RzE9mJjQTCkliJKOvv4HvU0tx56vU6yfHvGDpbdHSuVUSjb2wQ1G4leDojcoDg129tWf9h_I35V14OII_HDe7P-vJDaXX4-SPwFLl6hl</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Shimazu, Yutaka</creator><creator>Kanda, Junya</creator><creator>Suzuki, Kazuhito</creator><creator>Wada, Akinori</creator><creator>Kikuchi, Taku</creator><creator>Ikeda, Takashi</creator><creator>Tsukada, Nobuhiro</creator><creator>Miwa, Akiyoshi</creator><creator>Itagaki, Mitsuhiro</creator><creator>Kako, Shinichi</creator><creator>Nishiwaki, Kaichi</creator><creator>Ota, Shuichi</creator><creator>Fujiwara, Shin‐ichiro</creator><creator>Kataoka, Keisuke</creator><creator>Doki, Noriko</creator><creator>Sawa, Masashi</creator><creator>Hiramoto, Nobuhiro</creator><creator>Nishikawa, Akinori</creator><creator>Imai, Toshi</creator><creator>Ichinohe, Tatsuo</creator><creator>Kanda, Yoshinobu</creator><creator>Atsuta, Yoshiko</creator><creator>Kawamura, Koji</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6704-3633</orcidid><orcidid>https://orcid.org/0000-0002-8263-9902</orcidid><orcidid>https://orcid.org/0000-0002-1604-7220</orcidid></search><sort><creationdate>202407</creationdate><title>The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation</title><author>Shimazu, Yutaka ; Kanda, Junya ; Suzuki, Kazuhito ; Wada, Akinori ; Kikuchi, Taku ; Ikeda, Takashi ; Tsukada, Nobuhiro ; Miwa, Akiyoshi ; Itagaki, Mitsuhiro ; Kako, Shinichi ; Nishiwaki, Kaichi ; Ota, Shuichi ; Fujiwara, Shin‐ichiro ; Kataoka, Keisuke ; Doki, Noriko ; Sawa, Masashi ; Hiramoto, Nobuhiro ; Nishikawa, Akinori ; Imai, Toshi ; Ichinohe, Tatsuo ; Kanda, Yoshinobu ; Atsuta, Yoshiko ; Kawamura, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4048-7e4f221c5256c5f57153cd9df918efd8db2c1c4616feadd168a7638f1118cc123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Autografts</topic><topic>autologous stem cell transplantation</topic><topic>CD38 antigen</topic><topic>Chi-square test</topic><topic>Confidence intervals</topic><topic>daratumumab</topic><topic>Female</topic><topic>Gender</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - therapy</topic><topic>Multivariate analysis</topic><topic>Original</topic><topic>ORIGINAL ARTICLE</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>response</topic><topic>Retrospective Studies</topic><topic>Software packages</topic><topic>Stem cell transplantation</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimazu, Yutaka</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Suzuki, Kazuhito</creatorcontrib><creatorcontrib>Wada, Akinori</creatorcontrib><creatorcontrib>Kikuchi, Taku</creatorcontrib><creatorcontrib>Ikeda, Takashi</creatorcontrib><creatorcontrib>Tsukada, Nobuhiro</creatorcontrib><creatorcontrib>Miwa, Akiyoshi</creatorcontrib><creatorcontrib>Itagaki, Mitsuhiro</creatorcontrib><creatorcontrib>Kako, Shinichi</creatorcontrib><creatorcontrib>Nishiwaki, Kaichi</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><creatorcontrib>Fujiwara, Shin‐ichiro</creatorcontrib><creatorcontrib>Kataoka, Keisuke</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Sawa, Masashi</creatorcontrib><creatorcontrib>Hiramoto, Nobuhiro</creatorcontrib><creatorcontrib>Nishikawa, Akinori</creatorcontrib><creatorcontrib>Imai, Toshi</creatorcontrib><creatorcontrib>Ichinohe, Tatsuo</creatorcontrib><creatorcontrib>Kanda, Yoshinobu</creatorcontrib><creatorcontrib>Atsuta, Yoshiko</creatorcontrib><creatorcontrib>Kawamura, Koji</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimazu, Yutaka</au><au>Kanda, Junya</au><au>Suzuki, Kazuhito</au><au>Wada, Akinori</au><au>Kikuchi, Taku</au><au>Ikeda, Takashi</au><au>Tsukada, Nobuhiro</au><au>Miwa, Akiyoshi</au><au>Itagaki, Mitsuhiro</au><au>Kako, Shinichi</au><au>Nishiwaki, Kaichi</au><au>Ota, Shuichi</au><au>Fujiwara, Shin‐ichiro</au><au>Kataoka, Keisuke</au><au>Doki, Noriko</au><au>Sawa, Masashi</au><au>Hiramoto, Nobuhiro</au><au>Nishikawa, Akinori</au><au>Imai, Toshi</au><au>Ichinohe, Tatsuo</au><au>Kanda, Yoshinobu</au><au>Atsuta, Yoshiko</au><au>Kawamura, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2024-07</date><risdate>2024</risdate><volume>115</volume><issue>7</issue><spage>2384</spage><epage>2395</epage><pages>2384-2395</pages><issn>1347-9032</issn><issn>1349-7006</issn><eissn>1349-7006</eissn><abstract>The anti‐CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara– group) and those administered Dara (Dara+ group), the 1‐year progression‐free survival (PFS) rates were 87.4% and 77.3% and the 1‐year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara– group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.
To clarify the prognostic impact of daratumumab (Dara) before autologous stem cell transplantation (ASCT) on multiple myeloma (MM), we performed a retrospective observational analysis. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara– group.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>38757410</pmid><doi>10.1111/cas.16198</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6704-3633</orcidid><orcidid>https://orcid.org/0000-0002-8263-9902</orcidid><orcidid>https://orcid.org/0000-0002-1604-7220</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2024-07, Vol.115 (7), p.2384-2395 |
| issn | 1347-9032 1349-7006 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11247619 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; PubMed Central |
| subjects | Adult Age Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Autografts autologous stem cell transplantation CD38 antigen Chi-square test Confidence intervals daratumumab Female Gender Hematopoietic Stem Cell Transplantation - methods Humans Male Medical prognosis Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - therapy Multivariate analysis Original ORIGINAL ARTICLE Prognosis Progression-Free Survival response Retrospective Studies Software packages Stem cell transplantation Transplantation, Autologous Treatment Outcome |
| title | The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A02%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20daratumumab%20pretreatment%20on%20multiple%20myeloma%20patients%20undergoing%20autologous%20transplantation&rft.jtitle=Cancer%20science&rft.au=Shimazu,%20Yutaka&rft.date=2024-07&rft.volume=115&rft.issue=7&rft.spage=2384&rft.epage=2395&rft.pages=2384-2395&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.16198&rft_dat=%3Cproquest_pubme%3E3079030812%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3079030812&rft_id=info:pmid/38757410&rfr_iscdi=true |